View in EDS

Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer.

Saved in:
Bibliographic Details
Title: Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer.
Authors: Scott JS; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Evans L; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Astles PC; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Argyrou A; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Beattie D; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Braybrooke EL; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cassar DJ; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Crafter C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Diène C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Fairley G; Oncology R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Fallan C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Fraser G; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Galeano-Dalmau N; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Hammond TG; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Hock AK; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Jones T; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Komen J; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Michaloglou C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Niedbala MJ; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States., Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Rodrigo-Brenni MC; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Packer MJ; Oncology R&D, AstraZeneca, Macclesfield SK10 2NA, U.K., Pearson S; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Pike A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Schade M; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Shaw J; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K., Shologu Z; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Steward O; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Source: Journal of medicinal chemistry [J Med Chem] 2026 Feb 12; Vol. 69 (3), pp. 3209-3232. Date of Electronic Publication: 2026 Jan 29.
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41612563
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Scott+JS%22">Scott JS</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Evans+L%22">Evans L</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Astles+PC%22">Astles PC</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Argyrou+A%22">Argyrou A</searchLink>; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Bagal+SK%22">Bagal SK</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Beattie+D%22">Beattie D</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Braybrooke+EL%22">Braybrooke EL</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Cassar+DJ%22">Cassar DJ</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Crafter+C%22">Crafter C</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Diène+C%22">Diène C</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Fairley+G%22">Fairley G</searchLink>; Oncology R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.<br /><searchLink fieldCode="AU" term="%22Fallan+C%22">Fallan C</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Fraser+G%22">Fraser G</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Galeano-Dalmau+N%22">Galeano-Dalmau N</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Hammond+TG%22">Hammond TG</searchLink>; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Hock+AK%22">Hock AK</searchLink>; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Jones+T%22">Jones T</searchLink>; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Komen+J%22">Komen J</searchLink>; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Lamont+GM%22">Lamont GM</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Michaloglou+C%22">Michaloglou C</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Niedbala+MJ%22">Niedbala MJ</searchLink>; Oncology R&D, AstraZeneca, Waltham, Massachusetts 02451, United States.<br /><searchLink fieldCode="AU" term="%22Ramos-Montoya+A%22">Ramos-Montoya A</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Rodrigo-Brenni+MC%22">Rodrigo-Brenni MC</searchLink>; Safety Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Packer+MJ%22">Packer MJ</searchLink>; Oncology R&D, AstraZeneca, Macclesfield SK10 2NA, U.K.<br /><searchLink fieldCode="AU" term="%22Pearson+S%22">Pearson S</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Pike+A%22">Pike A</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Schade+M%22">Schade M</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Shaw+J%22">Shaw J</searchLink>; Discovery Sciences, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Shologu+Z%22">Shologu Z</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Steward+O%22">Steward O</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229716531%22">Journal of medicinal chemistry</searchLink> [J Med Chem] 2026 Feb 12; Vol. 69 (3), pp. 3209-3232. <i>Date of Electronic Publication: </i>2026 Jan 29.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Chemical+Society%22">American Chemical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9716531 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1520-4804 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200222623%22">00222623 </searchLink><i>NLM ISO Abbreviation: </i>J Med Chem <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41612563
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1021/acs.jmedchem.5c03138
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3209
    Titles:
      – TitleFull: Discovery of AZD9750, an Orally Bioavailable Androgen Receptor Degrader for the Treatment of Prostate Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Scott JS
      – PersonEntity:
          Name:
            NameFull: Evans L
      – PersonEntity:
          Name:
            NameFull: Astles PC
      – PersonEntity:
          Name:
            NameFull: Argyrou A
      – PersonEntity:
          Name:
            NameFull: Bagal SK
      – PersonEntity:
          Name:
            NameFull: Beattie D
      – PersonEntity:
          Name:
            NameFull: Braybrooke EL
      – PersonEntity:
          Name:
            NameFull: Cassar DJ
      – PersonEntity:
          Name:
            NameFull: Crafter C
      – PersonEntity:
          Name:
            NameFull: Diène C
      – PersonEntity:
          Name:
            NameFull: Fairley G
      – PersonEntity:
          Name:
            NameFull: Fallan C
      – PersonEntity:
          Name:
            NameFull: Fraser G
      – PersonEntity:
          Name:
            NameFull: Galeano-Dalmau N
      – PersonEntity:
          Name:
            NameFull: Hammond TG
      – PersonEntity:
          Name:
            NameFull: Hock AK
      – PersonEntity:
          Name:
            NameFull: Jones T
      – PersonEntity:
          Name:
            NameFull: Komen J
      – PersonEntity:
          Name:
            NameFull: Lamont GM
      – PersonEntity:
          Name:
            NameFull: Michaloglou C
      – PersonEntity:
          Name:
            NameFull: Niedbala MJ
      – PersonEntity:
          Name:
            NameFull: Ramos-Montoya A
      – PersonEntity:
          Name:
            NameFull: Rodrigo-Brenni MC
      – PersonEntity:
          Name:
            NameFull: Packer MJ
      – PersonEntity:
          Name:
            NameFull: Pearson S
      – PersonEntity:
          Name:
            NameFull: Pike A
      – PersonEntity:
          Name:
            NameFull: Schade M
      – PersonEntity:
          Name:
            NameFull: Shaw J
      – PersonEntity:
          Name:
            NameFull: Shologu Z
      – PersonEntity:
          Name:
            NameFull: Steward O
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 12
              M: 02
              Text: 2026 Feb 12
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1520-4804
          Numbering:
            – Type: volume
              Value: 69
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Journal of medicinal chemistry
              Type: main
ResultId 1